BioNTech Writes Down Its Pandemic Footprint as Monsanto Patent Fight Clears First Hurdle
Published on 09/29/2026 at 11:01 | Editorial boerse-global.de
BioNTech is dismantling the industrial base it built during the pandemic, and a federal judge in Delaware has just ensured that its legal exposure will run in parallel. The Mainz-based biotech confirmed it will close three German production sites — Tübingen, Marburg and Idar-Oberstein — after failing to find industrial buyers for the facilities, a retreat that will eliminate as many as 1,860 positions.
Manufacturing of the COVID-19 vaccine is being handed over entirely to Pfizer. Wind-downs are staggered: TĂĽbingen ceases operations at the end of 2027, Marburg follows in early 2028, and production in Idar-Oberstein runs out at the end of 2028. A site in Singapore is also caught up in the measures, according to Reuters. Works councils have agreed on socially compatible arrangements and additional severance payments. The Berlin subsidiary JPT Peptide Technologies, which employs roughly 130 people, has been sold to Dubag.
The root cause is structural: persistent overcapacity and a sharply cooled global appetite for COVID-19 shots. A changed investment climate scuppered the hoped-for sale of the plants to contract manufacturers. From 2029, management expects recurring annual savings of about EUR 500 million — capital that is to be funneled into clinical development of cancer drugs, reducing the group's reliance on pandemic-era revenue.
A EUR 1.35 Billion Loss and a Leadership Handover
Financial pressure has intensified. In the first half of 2026, BioNTech posted a net loss of EUR 1.35 billion, widening from a deficit of EUR 802.4 million a year earlier. Heavy research and development spending is weighing on the balance sheet, though the company still held roughly EUR 16.6 billion in cash and securities at the end of June. The stock closed yesterday at EUR 87.25 and was trading 1.1% lower at EUR 86.25 today.
Alongside the restructuring, a generational change at the top is approaching. Co-founders Ugur Sahin and Ă–zlem TĂĽreci intend to leave BioNTech by the end of 2026 at the latest to build a new company. Leadership is to pass to Oelkers by February 1, 2027 at the latest, and he will be responsible for executing the oncology strategy.
Should investors sell immediately? Or is it worth buying BioNTech?
That transition leaves investors in an awkward spot: the founders' attention may be split, and share sales by CEO Sahin under an existing trading plan send signals that could quickly breed sustained skepticism if the company's own pipeline slips.
Monsanto's mRNA Claims Survive an Early Test
On the legal front, a federal judge in Delaware rejected a motion by Pfizer, BioNTech and Moderna to dismiss patent suits brought by Bayer and Monsanto. The dispute centers on mRNA stabilization techniques that Bayer says were originally developed for plant research in the 1980s. The court ruled that at this early stage of proceedings neither patent invalidity nor non-infringement had been sufficiently demonstrated, meaning the case will proceed.
The ruling carries meaningful financial uncertainty. Should the litigation lead to retroactive licensing payments or damages awards, outflows could be painful — and combined with the restructuring costs of the German job cuts, liquidity reserves would erode faster than the market hopes.
The Oncology Bet That Has to Pay Off
The central question for valuation is how quickly BioNTech can align fixed operating expenses with real demand. Maintaining unused capacity had been an increasing drag on the balance sheet as exceptional vaccine revenue largely ran dry. Closing the three German plants is a decision against expensive standby capacity and in favor of a markedly lower operating cost base.
With a market capitalization of EUR 21.79 billion, BioNTech still has a substantial financial foundation, but the market no longer rewards pure liquidity cushions without operating visibility. If up to 1,860 jobs go, personnel costs fall noticeably — yet the savings must be large enough to cushion high oncology research spending without slowing the pipeline.
One source of optimism is gotistobart, developed jointly with OncoC4. In previously treated patients with squamous non-small cell lung cancer, gotistobart nearly doubled median overall survival compared with standard chemotherapy. Should those data hold up in further analyses, BioNTech gains access to a billion-dollar market beyond infectious diseases, and the removal of excess capacity lowers the break-even threshold for future products.
The stock's recovery in recent months points to a degree of resilience — it currently trades 26% above its 52-week low. If savings from the plant closures demonstrably accelerate late-stage clinical programs, the shares would gradually be valued again on their oncology assets rather than on fading COVID revenue.
For now, the market is treating the site closures as a consistent clean-up of the cost base, and the scenario holds as long as the stock defends recent support. Sentiment could flip on adverse developments in the US patent fight with Monsanto, or if savings from the job cuts are delayed. Operationally, investors' attention now turns to execution of the plant closures — the milestones that will show whether BioNTech can complete its transformation into a pure-play oncology specialist without lasting damage to its substance.
Ad
BioNTech Stock: New Analysis - 29 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
